Canaccord analyst Kyle Mikson lowered the firm’s price target on 10x Genomics to $50 from $65 and keeps a Buy rating on the shares. The firm believes the recent selloff has provided an attractive opportunity to accumulate shares of the company with potential catalysts and notes management could share updates related to their strategies for targeting focused markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Cathie Wood’s ARK Investment buys 116.4K shares of 10x Genomics today
- 10x Genomics price target lowered to $55 from $60 at Deutsche Bank
- 10x Genomics price target lowered to $45 from $55 at Barclays
- Cathie Wood’s ARK Investment bought 138K shares of 10x Genomics today
- Cathie Wood’s ARK Investment bought 241K shares of 10x Genomics today
